Long-lasting response with polycythemia to third-line axitinib treatment in metastatic renal cell carcinoma: Very rare case presentation

Abstract

Introduction

Clear cell renal cell carcinoma is characterized by mutation or inactivation of Von Hippel-Lindau suppressor gene. The mutation of Von Hippel-Lindau mechanism is associated with the upregulation of the hypoxia-inducible factor protein, inducing the overexpression of proteins including erythropoietin and vascular endothelial growth factor. Vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitors are widely used in treatment of metastatic renal cell carcinoma. In paradoxical hematological effect with tyrosine kinase inhibitor therapies, hemoglobin level may be increased, but polycythemia requiring phlebotomy is very rare.

Case description

We present here a case of renal cell carcinoma who received successive treatment with sunitinib, everolimus, and axitinib. While he had a normal hemoglobin level with prior sunitinib treatment, on the sixth week of axitinib treatment, he developed polycythemia and treatment response was seen after axitinib-associated polycythemia.

Conclusion

Progression-free survival (PFS) was 30 months in our case with third-line treatment axitinib. Higher hemoglobin levels may be associated with longer survival. Polycythemia was the first response to treatment of axitinib in our patient. It may be an indicator of persistent treatment response.

Keywords

Axitinib erythropoietin polycythemia renal cell carcinoma

Get full access to this article

View all access options for this article.

References

Kaelin

Jr . The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol 2003; 14: 2703–2711.

Feng

Ding

Song

et al.

Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma. Tumour Biol 2013; 34: 3471–3476.

Fandrey

. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 2004; 286: R977–R988.

Minardi

Lucarini

Filosa

et al.

Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Immunopathol Pharmacol 2008; 21: 447–455.

Ito

Yoshii

Asano

et al.

Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma. Exp Ther Med 2012; 3: 937–944.

Tripathi

Jacobus

Feldman

et al.

Prognostic significance of increases in hemoglobin in renal cell carcinoma patients during treatment with VEGF-directed therapy. Clin Genitourin Cancer 2017; 15: 396–402.

Rini

Escudier

Tomczak

et al.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378: 1931–1939.

Johnson

Matias

Boyle

et al.

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study. BMC Cancer 2017; 17: 355–355.

Alexandre

Billemont

Meric

et al.

Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 472–473; author reply 3–4.

10.

Alexandrescu

McClure

Farzanmehr

et al.

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 2008; 26: 4047–4048.

11.

Richard

Croisille

Yvart

et al.

Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 2002; 99: 3851–3853.